TARGET-BASED METHOD FOR HIGH-THROUGHPUT AND SUBCLASS SPECIFIC IgG GLYCAN PROFILING IN HUMAN PLASMA
US-2024353417-A1 · Oct 24, 2024 · US
USRE45992E · US · E1
| Field | Value |
|---|---|
| Publication number | US-RE45992-E |
| Application number | US-201014338413-A |
| Country | US |
| Kind code | E1 |
| Filing date | Mar 19, 2010 |
| Priority date | Mar 20, 2009 |
| Publication date | May 3, 2016 |
| Grant date | May 3, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.
Opening claim text (preview).
The invention claimed is: 1. A variant of a parent polypeptide comprising a Fc region, which variant exhibits increased binding to FcRn as compared to said parent polypeptide and comprises a combination of amino acid modifications selected from the group consisting of: N315D/A330V/N361D/A378V/N434Y, V264E/N315D/A378V/N390S/G420R/N434Y, N315D/A378V/N434Y, N315D/A330V/A378V/N434Y, N315D/K334E/A378V/N434Y, V264E/N315D/A378V, P228R/N315D/A330V/N361D/A378V/N434Y, P228R/P230S/N315D/A330V/N361D/A378V/N434Y, P228L/N315D/A330V/N361D/A378V/N434Y, P228L/P230S/N315D/A330V/N361D/A378V/N434Y, P230S/N315D/A330V/N361D/A378V/N434Y, P230T/V264E/N315D/K370R/A378V, of the Fc region, wherein the numbering of the amino acids in the Fc region is that of the EU index as in Kabat. 2. The variant according to claim 1 , wherein said variant is an antibody. 3. The variant according to claim 2 , wherein said antibody is an IgG antibody. 4. A pharmaceutical composition comprising a variant as defined in claim 1 . 5. A medicament comprising a variant according to claim 1 . 6. An isolated nucleic acid encoding a variant as defined in claim 1 . 7. A vector comprising the nucleic acid of claim 6 . 8. An isolated host cell containing the vector of claim 7 . 9. A method for producing a variant according to claim 1 , comprising culturing a host cell containing a vector comprising an isolated nucleic acid encoding said variant so that the nucleic acid is expressed. 10. A variant according to claim 1, wherein the Fc region of the parent polypeptide is SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4.
Drugs for immunological or allergic disorders · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Drugs for disorders of the nervous system · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.